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The a-Galactosyl Epitope: Minireview
A Sugar Coating That Makes
Viruses and Cells Unpalatable
Russell P. Rother and Stephen P. Squinto potentiated by an infectious agent that either carried
the a-galactosyl epitope or used it as a receptor. Indeed,Department of Molecular Development
epitopes reactive with anti-Gal have been detected onAlexion Pharmaceuticals
several potential pathogens including enveloped vi-New Haven, Connecticut 06511
ruses, bacteria, and protozoa (reviewed in Galili, 1993).
A reciprocal relationship exists between a-galactosyl
epitope expression and production of anti-Gal; the ab-
Exposure of nonprimate cells, tissues, and organs to
sence of this epitope in Old World primates correlates
human blood typically results in a rapid form of rejection
with production of anti-Gal in these species. In humans,
that is mediated by high-titer naturally occurring anti-
as much as 1% of the total serum IgG is specific for the
bodies and complement. This hyperacute rejection
a-galactosyl moiety. Significant levels of anti-Gal IgM
presents a formidable barrier to the use of nonprimate
and IgA have also been reported. It has been hypothe-
animals as transplant donors. The major xenoantigen sized that elevated levels of anti-Gal persist due to con-
responsible for such rejection has recently been identi- stant antigenic stimulation by a-galactosyl-like epitopes
fied as a single carbohydrate structure, the a-galactosyl found on the surface of bacteria constituting the normal
epitope. This epitope is expressed on the cells of most flora, as has been proposed for the production of anti-
mammals, with the exception of humans and other Old blood group antibodies (reviewed in Galili, 1993).
World primates. Conversely, the anti-a-galactosyl anti- The a-Galactosyl Epitope in Natural Immunity
body (anti-Gal) is unique to Old World primates. Type C retroviruses from various species often show a
Complement-mediated inactivation of certain type C wide in vitro host range, and sequence analysis indi-
retroviruses is also restricted to Old World primates, an cates that interspecies transmission of these viruses has
observation that has recently prompted the question of occurred during evolution. However, type C retroviruses
whethercomplementactivationbytheseviruses involves are rapidly inactivated in human serum in vitro (Welsh et
anti-Gal. Two decades ago, this species-restricted viral al., 1975). Over 15 years ago, such retroviral inactivation
inactivation was attributed to an antibody-independent was attributed to an innate immune mechanism medi-
mechanism mediated by direct activation of comple- ated by direct binding of C1q (which initiates the classi-
ment by the virus. However, recent studies now chal- cal complement pathway) to the retroviral envelope pro-
lenge this hypothesis and suggest that viral inactivation tein, p15E (Cooper et al., 1976; Bartholomew et al.,
occurs through an antibody-dependent mechanism that 1978). However, two recent studies have challenged this
is initiated by anti-Gal. Understanding the mechanisms long-standing hypothesis by identifying an antibody-
responsible for serum inactivation of retroviruses has dependent mechanism as the predominant mediator of
become increasingly important in the field of retroviral- viral inactivation. Natural antibody specific for the enve-
mediated gene transfer, as in vivo applications have lope-associated a-galactosyl epitope was shown to be
now entered the clinic. In this review we discuss the primarily responsible for complement activation and vir-
significance of anti-Gal and its carbohydrate epitope in olysis of murine-derived retroviruses in Old World pri-
retroviral-mediated gene transfer and xenotransplanta- mate sera (Rother et al., 1995). This inactivation was
tion and the possible contribution of this antibody– effectively inhibited by blockade of anti-Gal or down-
antigen interaction to natural immunity in humans. regulation of the a-galactosyl epitope. These results
The a-Galactosyl Epitope and Natural were confirmed by Takeuchi et al. (1996), who further
Antibody Recognition demonstrated that type C retroviruses propagated
The a-galactosyl epitope (Gala1–3Galb1–4GlcNAc-R) is through human cells expressing an exogenous a1–
a glycosidic moiety that is expressed on the surface of 3galactosyl transferase gene acquire sensitivity to hu-
cells from most mammalian species excluding humans man serum killing. Based onthese findings and an earlier
and other Old World primates (catarrhine primates). Ad- report indicating that retroviruses produced in human
dition of this epitope to lipids and proteins occurs in the cells display reduced complement sensitivity (Takeuchi
Golgi apparatus via transfer of galactose from the sugar et al., 1994), it has been proposed that propagation of
donor nucleotide, uridine diphosphate galactose (UDP- retrovirus in cells that do not express the a-galactosyl
galactose), to the acceptor N-acetyllactosaminyl group epitope will generate complement-resistant virus.
(Figure 1, reaction A). The enzyme that mediates this Complement-mediated inactivation of retroviruses in
transfer is a1–3galactosyl transferase, a protein that is human serum triggered by anti-Gal represents a unique
absent in Old World primates. Transcription from the type of natural immunity. Antibodies are normally con-
a1–3galactosyl transferase gene in Old World primates sidered to be an element of acquired immunity elicited
is undetectable, and nonsense mutations are present in response to a specific foreign antigen. In contrast,
within the coding region of some species. The presence anti-Gal is preformed and recognizes a carbohydrate
of a functional a1–3galactosyl transferase in New World moiety that is present on a variety of viruses.
monkeys indicates that this gene was inactivated after Prior to identification of anti-Gal, several studies re-
the divergence of Old and New World primates approxi- ported naturally occurring antibody that recognized en-
mately 40 million years ago. It has been speculated that velope glycoproteins from various type C retroviruses.
a1–3galactosyl transferase gene null mutations in Old It is likely that the natural antibody described in these
early studies recognized the a-galactosyl epitope. ForWorld primates were selected following an epidemic
Cell
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Figure 1. Terminal Enzymatic Reactions Leading to the Generation of the a-Galactosyl Epitope or H-Antigen
(A) Transfer of UDP-galactose to the N-acetyllactosaminyl group in an a1–3 linkage.
(B) Transfer of UDP-fucose to the N-acetyllactosaminyl group in an a1–2 linkage. The bolded arrow signifies the dominance of a1–2fucosyl
transferase over a1–3galactosyl transferase in competing for the common N-acetyllactosaminyl acceptor group.
example, envelope glycoproteins were only targeted by The occurrence of zoonotic diseases does not rule
out a role for anti-Gal in natural immunity against someantibody when the retroviruses were grown in non–Old
World primate cells. In addition, serum proteins from viruses. Effective elimination of viruses expressing the
a-galactosyl epitope is likely tobe dependent on severalNew World primates or other mammalian species, but
not Old World primates, shared the envelope glycopro- factors including route of transmission and viral dose.
For example, viruses introduced through aerosol trans-tein determinants recognized by the natural antibody.
These data suggest that the a-galactosyl epitope may mission will not initially encounter high-titer anti-Gal IgG.
Although gamma A class secretory anti-Gal may be en-be commonly associated with the envelopes of many
different retroviruses when passaged through cells that countered during this mode of transmission, IgA is a
poor activator of complement and its binding has beenexpress a functional a1–3galactosyl transferase (refer-
ences can be found in Barbacid et al., 1980). shown to actually protect some bacteria from comple-
ment lysis (Hamadeh et al., 1995). In addition, if inactiva-In addition to retroviruses, other enveloped viruses
contain proteins and/or lipids that bear the a-galactosyl tion of a particular virus by anti-Gal is complement de-
pendent, concentration of complement at the site ofepitope.The envelope of the eastern equine encephalitis
virus has recently been shown to incorporate a-galacto- viral entry may play a critical role. Finally, the size of
the initial dose of virus could determine the differencesyl modified glycoproteins when propagated through
murine but not Old World primate cells (Repik et al., between pathogenesis or viral clearance. If a single vi-
rion escapes anti-Gal-mediated inactivation and is am-1994). Other enveloped viruses, including the lympho-
cytic choriomeningitis virus (LCMV) and Newcastle dis- plified in a human cell, it will no longer express the
a-galactosyl epitope and could more readily spread toease virus, acquire sensitivity to human serum when
passaged through cells that express a1–3galactosyl other cells. By the same token, once a virus successfully
infects one individual, transmission to other humans willtransferase (Welsh, 1977). Conversely, LCMV grown in
human cells or a-galactosyl epitope-deficient baby not be subject to inactivation through this mechanism.
Implications in Retroviral-Mediated Gene Therapyhamster kidney cells is completely resistant to human
serum killing. Although the a-galactosyl epitope has not The role of the a-galactosyl epitope in serum killing of
retroviruses has important implications in the field ofbeen identified on thesurface of these viruses, the paral-
lel between serum sensitivity and cell passage history retroviral-mediated gene therapy. Although the transfer
of genes via retroviral particles has proven successfulstrongly suggests its presence.
The potential importance of human anti-Gal in provid- ex vivo, gene transfer in vivo has been primarily re-
stricted to nonprimate species. One of the major obsta-ing natural immunity against enveloped viruses originat-
ing from animal species that express the a-galactosyl cles to in vivo retroviral gene transfer in Old World
primates, including humans, is the rapid complement-epitope is not known. Conservation of high-titer anti-
Gal expression in Old World primates, including humans, mediated inactivation of murine-derived retroviruses in
primate blood. The observation that retroviral inactiva-suggests a critical function for this immunoglobulin.
However, the occurrence of human zoonotic diseases tion is mediated through recognition of the a-galactosyl
epitope has thus prompted attempts to prevent incorpo-such as influenza, rabies, and vesicular stomatitis sug-
gests that this antibody is not a strong impediment to ration of this carbohydrate structure into viral envelopes.
One strategy that has recently been employed to gen-cross-species transfer of all viruses. Furthermore,
agammaglobulinemia patients, who should lack this erate serum-resistant retroviruses involves the manipu-
lation of currently available high-titer retroviral producertype of immunological barrier, do not appear to show a
higher incidence of such zoonotic infections. cells. This strategy is based on previous observations
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showing that competition between glycosyl transfer- 1995). It is likely that survival of transplanted xenogeneic
cells in tissues that are exposed to higher levels of anti-ases for a common acceptor can determine which termi-
nal glycosidic residues are added. The N-acetyllacto- body and complement can also be potentiated by ma-
nipulation of the a-galactosyl epitope.saminyl group (shown in Figure 1) is the acceptor for
sugars from at least five glycosyl transferases in mam- Safety Considerations
It has been observed that intravenous administrationmalian cells, including a1–3galactosyl transferase and
a1–2fucosyl transferase (H-transferase). H-transferase of replication-competent murine amphotropic retrovirus
does not cause disease in Old World primates (Cornettagenerates the terminal glycosidic structure H-antigen
(corresponding to the O blood group phenotype), which et al., 1990). In this study, retrovirus was generated from
murine cells and would be expected to express a-galac-is universally compatible in human blood transfusions.
A recent study has shown that expression of recombi- tosyl residues. By contrast, replication-competent Mo-
loney murine leukemia virus introduced into primatenant H-transferase in cells containing a functional a1–
3galactosyl transferase gene results in elevated expres- stem cells ex vivo has been shown to induce T cell
lymphoma in rhesus monkeys following bone marrowsion of H-antigenmodified membrane proteins (Figure 1,
reaction B) with a concomitant reduction in a-galactosyl reconstitution (Donahue et al., 1992). The pathogenicity
of this retrovirus may reflect the absence of the a-galac-epitope expression (Sandrin et al., 1995). Using this
same strategy, it has been demonstrated that expres- tosyl epitope on the viral envelope following passage
through primate cells, although duplication of a coresion of H-transferase in retroviral producer cells effec-
tively reduces the level of a-galactosyl residues on the enhancer element in recombinant retrovirus isolated
from the lymphoma cells has recently been implicatedcell surface and renders both cells and virus resistant
to complement-mediated damage (Rother et al., 1995). as the pathogenic factor (Purcell et al., 1996). The gener-
ation of a1–3galactosyl transferase gene knockout mice,Cells that are deficient in a-galactosyl epitope expres-
sion are also good candidates for the generation of cell which have been shown to produce anti-Gal (Thall et
al., 1995), should provide a model for assessing thelines that produce serum-resistant retrovirus. Such cells
include those of humans and other Old World primates. importance of this antibody in immunity against replica-
tion-competent retrovirus.Human producer cells have already been reported to
produce retrovirus that is resistant to inactivation in hu- Taken together, these data underscore the need for
stringent assays to detect replication-competent retro-man serum (Cosset et al., 1995). In addition, producer
lines can be generated from nonprimate cells that do virus in viral populations produced for administration to
humans. Although the introduction of various deletionsnot express the a-galactosyl epitope. These include nat-
urally deficient cells such as baby hamster kidney or and mutations in the helper virus genome and the sepa-
ration of helper virus coding regions (gag-pol and env)Chinese hamster ovary, as well as cells obtained from
a1–3galactosyl transferase gene knockout mice. in packaging cell lines have decreased the generation
of replication-competent retroviruses, evidence that en-The Role of the a-Galactosyl Epitope
in Xenotransplantation dogenous viral sequences found in eukaryotic cells may
also participate in recombination events has been dem-Upon establishing circulation to a nonprimate xenoge-
neic organ transplanted into an Old World primate, com- onstrated (Purcell et al., 1996). This issue has recently
been addressed through the generation of packagingplement is activated and blood flow to the organ ceases
within minutes. This hyperacute form of graft rejection cell lines in which the retroviral vector and packaging
cell are derived from different species in hope of elimi-is primarily mediated by recognition of the a-galactosyl
epitope on the surface of xenogeneic endothelial cells nating the occurrence of endogenous sequences that
can recombine with the vector (Cosset et al., 1995).by anti-Gal. Efforts are now underway to reduce or elimi-
nate the expression of this epitope in transgenic ani- Concerns that human pathogens may be generated
through the elimination of the a-galactosyl epitope aremals.These include down-regulation of the a-galactosyl
epitope through the expression of H-transferase and also relevant to the field of xenotransplantation. Based
on anatomical, physiological, and ethical considera-the targeted knockout of the a1–3galactosyl transferase
gene. Other strategies toabrogate this antibody–antigen tions, the primary donor candidate for xenotransplanta-
tion into humans is the pig. Questions have been raisedinteraction include transient depletion of anti-Gal in the
circulation through extracorporeal absorption and anti- regarding the possibility of infecting recipients with po-
tentially pathogenic retroviruses from the porcine donor.body blockade using synthetic carbohydrates (refer-
ences can be found in Sandrin et al., 1995). Removal of the a-galactosyl epitope in porcine organs
or removal of anti-Gal in the recipient may increase theCultured cells from nonprimate species are also being
utilized in transplantation. For example, murine-derived possibility of interspecies retroviral transmission by af-
fecting natural immunity against the virus. Efforts areretrovirus producer cells have recently been introduced
into humans as a means of increasing transduction effi- currently underway to isolate and characterize porcine-
derived retroviruses and assess their potential dangerciency. However, recent evidence shows that murine
producer cells are rapidly killed in human serum, primar- to humans. A better understanding of the a-galactosyl
epitope and its potential role in restricting the interspe-ily through anti-Gal-mediated complement lysis (Russell
et al., 1995; Rollins et al., 1996). This is in contrast to cies transmission of viruses and other pathogens to
humans is needed for the development of safe and effi-datashowing that murine-derived producer cells survive
exposure to human cerebrospinal fluid; a finding that is cacious strategies of xenotransplantation, as well as
retroviral-mediated gene therapy.probably attributable to low levels of antibody and/or
complement in the central nervous system(Russell et al., The absence of the a-galactosyl epitope in humans
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and other Old World primates poses many fascinating
questions. Why do members of this lineage carry null
mutations in the a1–3galactosyl transferase gene, while
evolutionary pressures have conserved this enzymatic
activity in all other mammalian species? What is the
function of anti-Gal, and is this antibody an important
component of natural immunity against potential human
pathogens that carry the a-galactosyl epitope? Will the
risk of infection associated with the introduction of re-
troviruses and animal donor organs into patients be
increased by theelimination of the a-galactosyl epitope?
Recent findings have provided some tantalizing hints,
but there is much yet to learn concerning the signifi-
cance of anti-Gal and its carbohydrate epitope.
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